Author: Ryan Allway

TORONTO, June 18, 2018 (GLOBE NEWSWIRE) — James E. Wagner Cultivation Corporation (TSX VENTURE:JWCA) (“JWC” or the “Company“) is pleased to announce that it has entered into a letter of intent (“LOI“) with Medipharm Labs Inc. (“MediPharm“) pursuant to which the parties have agreed to negotiate a potential commercial arrangement whereby MediPharm will initiate a cannabis concentrate program for JWC that will involve JWC providing MediPharm with dried cannabis to use for the purposes of creating cannabis oil (the “Program“).

Upon execution of a definitive agreement in respect of the Program and subject to the bulk transfer approval of Health Canada, JWC will ship dried cannabis to MediPharm which MediPharm will use to produce cannabis oil. The parties intend that under the Program, MediPharm may provide cannabis oil to JWC or to other licensed producers of medical cannabis at the direction of JWC. Alternatively, JWC may release the cannabis extract for use by MediPharm. The Program will be established at no capital cost to JWC; however, MediPharm will charge JWC processing fees for the cannabis oil produced, and the revenue earned on sales of cannabis oil by MediPharm will be shared between MediPharm and JWC.

The parties intend that the term of the Program will be three years. This will provide JWC with a strategy for providing cannabis oil to patients.

Nathan Woodworth, JWC’s President and Chief Executive Officer, said: “JWC is a licensed producer of medical cannabis located in Kitchener, Ontario. By exclusively employing our proprietary aeroponic platform, GrowthStorm™, we are able to grow clean and consistent medical cannabis in our state of the art facility. JWC grew from starting as a family business, founded on family values. Since our inception as a group of patients and growers under the MMAR, we have remained focused on providing the best possible patient experience. We are very excited to enter into a relationship with MediPharm, which will allow us to provide our patients with convenient, effective edible cannabis oil products. The relationship with MediPharm will facilitate and expedite our ability to obtain the necessary licence amendments which will enable us to produce and then sell extract products derived from our quality-controlled plant material. We strongly believe that this is an important option for many patients, as an alternative method of dosing and ingestion. In its relationship with MediPharm, JWC will be able to provide a line of cannabis oils which will perfectly complement the other products offered by the Company.”

The implementation of the Program is subject to the completion of each parties’ due diligence and the negotiation and execution of a definitive agreement in respect of the Program.

About MediPharm Labs Inc.

MediPharm is a licensed producer of medical cannabis under the Access to Cannabis for Medical Purposes Regulations. MediPharm is Canada’s first Licensed Producer approved solely for cannabis oil production. MediPharm anticipates receiving its license to sell cannabis oil in fall 2018. MediPharm produces a number of cannabis concentrate products approved by Health Canada, including purified cannabinoids, sublingual drops, diluted cannabis oil, soft gel capsules, formulated vape cartridges and tabs and pills.

For additional information about MediPharm, please see the company’s website: www.medipharmlabs.com.

About James E. Wagner Cultivation Corporation

JWC is a premier cannabis business that focuses on growing its cannabis aeroponically, using cutting edge cannabis technologies and growing practices. Although many methods are used to produce cannabis under the Access to Cannabis for Medical Purposes Regulations, it is important to note that these methods will often result in a variety of different outcomes. Through its various proprietary technologies involved in all stages of the growing process, JWC prides itself on continuing to provide patients with clean, consistent medical cannabis products of high quality.

For additional information about JWC, please refer to JWC’s profile on SEDAR (www.sedar.com) or the Company’s website: https://www.jwcmed.com/home.html 

Notice regarding forward-looking statements:

This press release contains forward-looking statements about JWC and its business which may include, but is not limited to, risk, uncertainties and other factors that may cause actual events to differ materially from current expectations. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting JWC. For example, there can be no guarantee that JWC will enter into a definitive agreement in respect of the Program, or that such definitive agreement will be negotiated on the same terms as set out in the LOI. Other risk factors include risks regarding the cannabis industry, economic factors, the equity markets generally and risks associated with growth and competition. Although JWC has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information about this release, please contact Nathan Woodworth, the President and Chief Executive Officer of JWC:

Email: nathan@jwcmed.com
Phone: (519) 594-0144 x421

VANCOUVER, British Columbia, June 18, 2018 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE:BLO) (OTC PINK:BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to report that recent testing with Beta 3.0 has shown the identification and first order separation of two key metabolites of ∆9-tetrahydrocannabinol (“THC”), being 11-hydroxy-delta-9-tetrahydrocannabinol and 11-nor-9-carboxy-tetrahydrocannabinol in standards. In addition, scientists have made significant progress towards using lower flow rates that will become important for user groups with poor lung function. Furthermore, engineers have been testing a new breath capture method that can hold THC breath samples in a stable manner for several days.

∆9-tetrahydrocannabinol (“THC”) the main psychoactive component of marijuana is metabolized into and 11-nor-9-carboxy-tetrahydrocannabinol at different rates based on route of entry into the body. Smoked THC is converted predominantly to 11-nor-9-carboxy-tetrahydrocannabinol which is then glucuronidated to a water-soluble form that can be detected in body fluids. Ingested THC is metabolized via the hepatic portal circulation to 11-hydroxy-delta-9-tetrahydrocannabinol prior to oxidation to 11-nor-9-carboxy-tetrahydrocannabinol. The Cannabix FAIMS device coupled to real time switchable mass spectrometry is actively being tuned to detect these key molecules and their complex pathways in the body to enable the identification of recency of use.

The recent passing of legislation Bill C-45 by the Senate of Canada and legislative developments in the State of Vermont, have increased the number of inquires for the Cannabix breathalyzer device and the Company has received interest in piloting from both U.S. and Canadian law enforcement groups as well as other organizations that drug test their employees. The Senate Judiciary Committee in the state of Vermont recently rejected a bill to use saliva testing for THC enforcement, amid concerns of scientific validity, accuracy, and infringement on civil liberties.

Rav Mlait, CEO, stated, “With the passing of Bill C-45 in Canada the growing problem of drugged driving will increasingly become an issue of paramount concern for federal, provincial and civic governmental officials and the public at large who are concerned about maintaining public safety on our roads, institutions and in our workplaces. A recent study by the Governors Highway Safety Association found that drugs are being detected more often in drivers responsible for fatal crashes. The problem of drugged driving is compounded by lack of nationally accepted method for testing drugged driver impairment. Cannabix Technologies has been at the forefront of research and development in this arena and understands the complexities related to breath testing for marijuana. As the issue of drugged driving becomes increasingly acute, Cannabix is committed to using its technology, R&D and scientific experience to provide effective tools to aid law enforcement and help governments and the public transition to marijuana legalization in various jurisdictions.”

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable hand-held tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many global jurisdictions. Cannabix is working to develop drug-testing devices that will detect THC- the psychoactive component of marijuana that causes intoxication- using breath samples. In particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects usage, days or even weeks earlier. The devices will also be useful for other practical applications such as testing employees in the workplace where impairment by THC can be hazardous.

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

VANCOUVER, British Columbia, June 18, 2018 (GLOBE NEWSWIRE) — FinCanna Capital Corp. (“FinCanna”) (CSE:CALI) a royalty company for the U.S. licensed medical cannabis industry, is pleased to announce that following higher than anticipated demand the Company has increased the size of its previously announced non-brokered private placement financing from C$3 million to C$5 million. FinCanna will now issue up to 16,666,667 Units at a purchase price of C$0.30 per Unit.

Each Unit will consist of one common share of FinCanna and one common share purchase warrant. Each full warrant will be exercisable to acquire one common share of FinCanna at an exercise price of $0.45 for 24 months from the date of the closing of the Private Placement.

FinCanna has agreed (i) to pay a cash finder’s fee of 8% of the aggregate proceeds raised from subscriptions arranged by certain finders and (ii) to issue warrants equal to 8% of the aggregate Units subscribed for pursuant to the subscriptions arranged by such finders. Each warrant shall be exercisable for one common share at a price of C$0.45 for a period of 24 months following the closing date of the Private Placement. The lead finder in the non-brokered private placement is TriView Capital Ltd., one of Canada’s largest Exempt Market Dealers.

The closing of the Private Placement is expected to occur on or about June 29, 2018 and is subject to the receipt of all necessary regulatory approvals, including the approval of the Canadian Stock Exchange. All securities issued pursuant to the Private Placement will be subject to a four-month hold period in accordance with applicable Canadian securities laws. There is no material fact or material change regarding FinCanna that has not been generally disclosed.

FinCanna intends to use the net proceeds from the Private Placement to fund additional royalty investment opportunities and the Company’s ongoing working capital and general corporate purposes.

This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “1933 Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the 1933 Act and applicable state securities laws or an exemption from such registration is available.

About FinCanna

FinCanna provides financing to top-tier companies in the licensed medical cannabis industry in exchange for a royalty on revenues. FinCanna, led by a team of finance and industry experts, is building its diversified portfolio of royalty investments in scalable, best-in-class projects and companies in U.S. legal states, with a focus on California. For additional information visit www.fincannacapital.com and FinCanna’s profile at www.sedar.com.

FinCanna Capital Corp.
Andriyko Herchak, CEO & Director

Investor Relations:

Arlen Hansen
Kin Communications
1-866-684-6730
CALI@kincommunications.com

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking information based on current expectations. Statements about, among other things, the closing of the Private Placement, expected terms and conditions of the Private Placement, the completion, terms and size of the Private Placement and the use of proceeds of the Private Placement are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such factors include but are not limited to: the ability to find suitable subscribers for the Private Placement. Although such statements are based on management’s reasonable assumptions at the date such statements are made, there can be no assurance that the Private Placement will occur or that, if the Private Placement does occur, it will be completed on the terms described above and that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking information. Accordingly, readers should not place undue reliance on the forward-looking information. FinCanna assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.

Scott Young, Telephone: +1.705.888.2756Copyright CNW Group 2018

VANCOUVER, British Columbia, June 14, 2018 (GLOBE NEWSWIRE) — RavenQuest BioMed Inc. (CSE:RQB) (the “Company” or “RavenQuest”) is pleased to announce that it has entered into a letter of intent with 1090252 B.C. Ltd. (“Elephant Extracts” or “Elephant”) in pursuit of a transaction involving the acquisition of 51% of the outstanding share capital of Elephant Extracts.

Elephant Extracts is a license applicant under the Access to Cannabis for Medical Purposes Regulations(“ACMPR”), as well as a distributor of cannabis products and accessories.  The Health Canada application for Elephant Extracts includes a 10,000 square foot production facility, which will be classified as a “micro-cultivator” license upon passing of the Cannabis Act in Canada.

RavenQuest CEO, George Robinson, commented, “We are very excited to welcome Trevor Hinds and his team at Elephant Extracts into the RavenQuest family.  Elephant’s vast extraction knowledge is a wonderful complement for RavenQuest’s revolutionary and science-based grow methodology, producing a powerful combination.”

“RavenQuest is committed to helping micro-cultivators come into the legalized space across the country,” Robinson continued.  “We expect this will be the first of many micro-cultivators to work with RavenQuest.  Our services division, which has helped several LPs become licensed, brings an expertise which is unmatched in the cannabis space.  Our experience in this highly regulated space brings precisely what is needed by the many micro-cultivators who wish to properly transition into the legalized space.”

Trevor Hinds, President & CEO of Elephant, noted, “RavenQuest has shown a clear and distinct interest in the role of the micro-cultivator as we move toward legalization.  We are very appreciative of RavenQuest’s recognition of the micro-cultivator’s value and are even more excited to join an organization with such clear leadership in the science of the cannabis plant.”

Under the terms of the transaction, RavenQuest will acquire a controlling interest (51%) in Elephant Extracts.  This interest can be redeemed by Elephant Extracts at any time after it receives a license to produce under the ACMPR, and in consideration RavenQuest will be granted an ongoing royalty of 15% of the gross revenue from production at the facility developed by Elephant Extracts.  Completion of the transaction with Elephant Extracts is subject to completion of due diligence, the negotiation of definitive documentation, and the receipt of any required regulatory approvals.

About RavenQuest BioMed Inc.

RavenQuest BioMed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development.

On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.

“George Robinson”
Chief Executive Officer

For further information, please contact:
Mathieu McDonald, Corporate Communications
604-484-1230

Neither Canadian Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Stock Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statements

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including statements with respect to completion of the acquisition of Elephant Extracts.  The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes.  By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved.  These risks and uncertainties include but are not limited to those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements.  The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

TORONTO, June 14, 2018 (GLOBE NEWSWIRE) — The Green Organic Dutchman Holdings Ltd. (the “Company” or “TGOD”) (TSX:TGOD) (OTCQX:TGODF) is pleased to announce it has entered into a strategic partnership with Epican Medicinals Ltd. This partnership will add an additional 14,000 kgs, taking TGOD’s total organic funded capacity to 130,000 kgs. Epican is a vertically integrated Jamaican cannabis company with cultivation, extraction, manufacturing and retail distribution licenses. This strategic partnership introduces TGOD’s premier organic cannabis brand to the international medical market.

“This represents the first of many strategic partnerships TGOD intends to execute in the coming months,” said Robert Anderson, CEO. “Our value-added approach taken in this investment will set an international M&A framework for capital investment, transfer of knowledge, and sector expertise. We will continue to evaluate international opportunities that will assist us in executing our business plan to become the world’s largest organic cannabis brand,” continued Anderson.

Epican produces high quality cannabis at its primary Blue Mountain cultivation site and has partnered with TGOD to construct a second 125,000 sq. ft. GMP compliant facility. Upon receiving the second site license, both facilities will cultivate high premium organic strains for the Jamaican and international markets. The Company will be working with Eco-Cert to achieve organic certification in Jamaica.

Epican’s extraction laboratory has been designed, licensed and built to GMP standards, establishing the company as a leader in sustainability with Jamaica’s Cannabis Licensing Authority (“CLA”). The company intends to sell a wide range of products such as dried flower, oils, pre-rolled joints, vapes, tinctures, among others. Epican’s initial offering of 11 scientifically formulated products will allow the company to service medical cannabis patients through its network of retail dispensaries (“Herb Houses”).

Jamaican dispensaries, known as Herb Houses, are crucial to the distribution of cannabis in Jamaica. Epican, with its first mover advantage, is opening its flagship dispensary in July 2018 located in Kingston, Jamaica. This will represent the first of many Herb Houses, with several more to be completed by the end of 2018 including locations along Jamaica’s northern coast. These locations will serve the medical needs of Jamaica’s 3 million residents and approximate 3.5 million visitors each year.

Jamaica has long been recognized as a premier location for cannabis enthusiasts and Epican has deep roots in the country. Founders, the McKenzie brothers, have been at the forefront of the nation’s burgeoning medical cannabis industry, including extensive advocacy for the responsible development of the industry. Epican’s social commitment to Jamaica’s agricultural community includes a partnership plan to support Jamaica’s Small Farmer Program. Epican was awarded the country’s historic first cultivation license.

International expansion is an integral part of TGOD’s business plan. The partnership with Epican will provide a low-cost platform from which TGOD is supplied premium Jamaican grown medical cannabis for export to select international jurisdictions, as regulations permit.

TGOD’s partnerships are more than an investment for a portfolio company. TGOD investments are structured as true partnerships, where portfolio companies receive countless hours of support and industry leading knowledge. This knowledge transfer includes cultivation methodology, extraction, R&D, and organic certification, through to accounting, auditing, sales, marketing, and distribution. This is exemplified in TGOD’s investment into Epican and Jamaica, by providing expertise to expedite Epican’s organic certification process through Eco-Cert, developing and refining its sales, marketing, and branding plans, outreach to all-inclusive resorts, and digital marketing focused on medical tourism.

Karibe McKenize, CEO of Epican, stated “We are excited to partner with and benefit from TGOD’s immense knowledge in organic cannabis cultivation. This expertise supports and enhances our authentic Jamaican production and ensures patients receive a product that is completely free from chemical pesticides and synthetic fertilizers. Our partnership with TGOD solidifies our commitment to producing cannabis in the most sustainable and natural methods possible, honouring Jamaica’s historic relationship with the natural and medicinal benefits of the plant.”

In conjunction with the Strategic Partnership Agreement, TGOD has entered into a binding agreement to invest into Epican for a 49.18% interest. Furthermore, TGOD will provide Epican access to its financing facilities to support future expansion requirements. The transaction is subject to customary regulatory and TSX approvals.

“This is the first example of how we can partner with and introduce companies like CBx Technologies and Stillwater Brands to foreign jurisdictions,” said Csaba Reider, the Company’s President. “Through the development of GMP compliant, state-of-the-art extraction labs, TGOD will begin manufacturing these proven brands in international jurisdictions as regulations permit,” continued Mr. Reider.

On Behalf of the Board of Directors,
The Green Organic Dutchman Holdings Ltd.
Robert Anderson
Chief Executive Officer and Co-Chairman

ABOUT THE GREEN ORGANIC DUTCHMAN HOLDINGS LTD.

The Green Organic Dutchman Holdings Ltd. is a research & development company licensed under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) to cultivate medical cannabis. The Company carries out its principal activities producing cannabis from its facilities in Ancaster, Ont., pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada) and its regulations.

The Company grows high quality, organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a funded capacity of 116,000 kg and is building 970,000 sq. ft. of cultivation facilities in Ontario and Quebec.

The Company has developed a strategic partnership with Aurora Cannabis Inc. (TSX:ACB) whereby Aurora has invested approximately C$78.1 million for an approximate 17.5% stake in TGOD. In addition, the Company has raised approximately C$315 million dollars and has over 20,000 shareholders.

TGOD’s Common Shares and warrants issued under the indenture dated November 1, 2017 trade on the TSX under the symbol “TGOD” and “TGOD.WT”, respectively.

CONTACT INFORMATION

Investor Relations
Email: invest@tgod.ca
Phone: 1 (416) 900-7621

www.tgod.ca

Forward-Looking Information Cautionary Statement

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward looking statements in this release includes, but is not limited to, statements about the future legalization of recreational cannabis and cannabis-infused products in Canada, statements about future research, development and innovation by the Company, statements about the offering of any particular products by the Company and statements regarding the future performance of the Company. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accept responsibility for the adequacy or accuracy of this release.

VANCOUVER, British Columbia, June 14, 2018 (GLOBE NEWSWIRE) — Quadron Cannatech Corporation (the “Company” or “Quadron”) – (CSE:QCC), is pleased to announce the progress of various projects initiated by Cybernetic Control Systems Inc. (“Cybernetic”), which was acquired by the Company as a division of Quadron in March 2017.

Cybernetic builds efficient, customized machine control solutions that provide various industries with innovative, machine automation and control systems. With the range of industries that Cybernetic can provide products for, there has been significant progress with its various products and services:

• Within the mining industry, Cybernetic provided a control system for a water treatment plant on a remote mine site, where continued programming and automation is provided for support.
• An agreement with Schneider Electric was extended to include power monitoring and quality products. These products can be used to monitor, analyze, sub-meter, report and improve power in Cybernetic’s and Soma Labs’ client facilities.
• Cybernetic secured a contract for a complete control system for a natural gas utility. This one of a kind system is used to test and calibrate natural gas regulators in a revolutionary, accurate and traceable manner.
• A $200,000 contract was secured for Cybernetic to provide turnkey solar powered off-road communications trailers to a major Canadian mining company. This contract can convert into a multi-million dollar contract to meet the mine’s immediate requirements after they test the initial units.

Rosy Mondin, CEO of Quadron Cannatech commented, “Since acquiring Cybernetic we are pleased with their progress and ability to provide automation and control system solutions to a variety of different industries. In addition to Cybernetic’s core business, they have played an instrumental role constructing and developing our BOSS CO2 Extractor and developing new extraction systems for the Company. Cybernetic’s expertise in automation continues to give Quadron a competitive edge in a growing extraction market and develop the best-in-class industrial scale equipment.”

About Cybernetic Control Systems Inc.:
Cybernetic provides custom or standard machines and control packages to various industries, including hydroponics, green energy, pharmaceutical, nutraceutical and the food industry. The Company offers technical services and equipment for process automation.

For more information, visit: www.quadroncannatech.com

On behalf of the Board of Directors of
QUADRON CANNATECH CORPORATION

Rosy Mondin
President and CEO
rosy@quadroncannatech.com

Investor Relations Contact:
KIN Communications Inc.
Caleb Jeffries, VP, Investor Relations
1-866-684-6730
QCC@kincommunications.com

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, including with respect to the scheduled closing date of the Offering and the intended use of the proceeds of the Offering, which are not historical in nature are intended to be, and are hereby identified as “forward-looking statements”.  Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company’s future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.

TORONTO, June 14, 2018 (GLOBE NEWSWIRE) — Maricann Group Inc. (CSE:MARI) (FRANKFURT:75M) (OTCQB:MRRCF) (“Maricann” or the “Company) is providing an update to the market regarding their recently announced letter of intent to acquire a license in Malta.

Following discussions with Malta Enterprise, the government entity responsible for the issuance of such licenses, the Company has submitted its own application for a license and has terminated its letter of intent to acquire Medican Holdings (“Medican”).

Initially, Medican had received initial approval and Maricann received confirmation of the same. Malta Enterprise then contacted Maricann to request the Company make its own application, as their preference was to work through Maricann rather than Medican. The Company then submitted its own application to Malta Enterprise who have acknowledged receipt. Maricann anticipates the application to be reviewed within the next 30 days with a decision on the approval status.

About Maricann Group Inc.

Maricann is a vertically integrated producer and distributor of marijuana for medical purposes. The company was founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the Government of Canada. The Company also has production operations in Dresden, Saxony, Germany and Regensdorf, Switzerland. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a 942,000 sq. ft. (87,515 sq. m) and will continue to pursue new opportunities in Europe.

Forward Looking Statements

This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company. Such statements include statements regarding the timing and ability to obtain a license in Malta. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

For more information about Maricann, please visit our website at www.maricann.com

CONTACT INFORMATION

Investor Relations
Graham Farrell
Director of Investor Relations
graham@maricann.com
647-643-7665

Corporate Headquarters (Canada)
Maricann Group Inc. (Toronto)
845 Harrington Court, Unit 3
Burlington Ontario L7N 3P3
Canada
289-288-6274

European Headquarters (Germany)
Maricann GmbH
Thierschstrasse 3, 80538 Munchen, Deutschland

Choom Holdings Inc., Chris Bogart, President & CEO, T: 604.683.2509, F: 604.683.2506, E: chris@choom.ca; Alex Porporo, Investor Relations, T: 604.683.2509, F: 604.683.2506, E: alex@choom.caCopyright CNW Group 2018

Damian Kettlewell, CEO, (604) 484 9119, ext. 3, damian.kettlewell@blissco.comCopyright CNW Group 2018

VANCOUVER, British Columbia, June 13, 2018 (GLOBE NEWSWIRE) — Crop Infrastructure Corp. (CSE:CROP) (OTCMKTS:CRXPF)  (“Crop” or the “Company”) announces that it has secured The Depository Trust Company (DTC) eligibility for its shares traded in the United States under the symbol CRXPF. The Company’s common shares traded on the OTC Market in the United States, under the symbol “CRXPF” are Depository Trust Company (“DTC”) eligible, effective June 12, 2018. The DTC will facilitate electronic settlement of transfers of its common shares in the United States.

Michael Yorke, CEO of Crop states: “Crop is registering its shares with DTC as a fundamental step towards establishing the company with the American investment community. The DTC’s electronic settlement of our shares is critical to having an effective market. Our goal is to graduate to a more senior exchange in the future, and expand our business endeavors globally.”

About DTC

The DTC is a subsidiary of the Depository Trust & Clearing Corporation and manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through the DTC are considered “DTC eligible.” This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors and brokers. Securities that are not DTC-eligible are often not accepted for trading at many brokerages due to the amount of paperwork and manpower required to execute and settle trades, thus making it more difficult for a significant percentage of investors to access the shares. Additionally companies that are approved for DTC electronic transfers often experience higher trading volumes in their stock given the additional accessibility and availability of shares for trading.

About CROP Infrastructure Corp.

CROP Infrastructure Corp. is engaged in the business of investing, constructing, owning and leasing greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations. CROP’s portfolio of projects includes greenhouse facilities in California and Washington State.

For more information about CROP Infrastructure Corp.

Michael Yorke – Director
E-mail: info@cropcorp.com
Phone: (604) 484-4206

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.

The securities of the Company are considered highly speculative due to the nature of the Company’s business. The Company is indirectly involved through its business in both the medical and recreational cannabis industry in the United State where local state law permits such activities. As a result of the conflicting views between state legislatures and the federal government regarding cannabis, investments in cannabis businesses in the United States are subject to inconsistent legislation and regulation and therefore there are risks of federal government enforcement. Marijuana-related practices or activities, including the cultivation, possession or distribution of marijuana, are illegal under U.S. federal law.

Forward-Looking Information

Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.

Statements about the Company’s business, plans and other statements, are all forward-looking information. Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs and the ability to achieve goals, that general business and economic conditions will not change in a material adverse manner, that the U.S. federal government will not prosecute people and companies who are involved directly or indirectly in the legal state cannabis industry, that financing will be available if and when needed and on reasonable terms, and that third party contractors, equipment and supplies and governmental and other approvals required to conduct the Company’s business will be available on reasonable terms and in a timely manner. While such estimates and assumptions are considered reasonable by the management of the Company, they are inherently subject to significant business, economic, competitive and regulatory uncertainties and risks.

Factors that could cause the actual results to differ materially from those in forward-looking statements include, failure to obtain regulatory approvals, increase in construction and operating costs, government regulations, changes in laws and the enforcement of such laws, in particular the laws of the Unites States, lack of tenants at the Company’s joint-venture facilities, loss of key employees and consultants, the continued availability of capital and financing, general economic conditions, competition, litigation, market or business conditions. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. These assumptions, risks and uncertainties include, among other things, including, but not limited to: regulatory and political risks, in particular those of the United States; change in laws, regulations and guidelines; limited operating history; competition; risks inherit ant in an agricultural business; vulnerability to rising energy costs; environmental and employee health and safety regulations; lack of demand of the Company’s services; dependence on suppliers and skilled labour; reliance on key inputs; operating risk and lack of initial insurance coverage; unfavourable publicity or consumer perception; operation permits and authorizations; risks associated with acquisitions; risks associated with loaned money; financial projections may prove materially inaccurate or incorrect; management of growth; difficulty implementing business strategy; costs of maintaining a public listing; conflicts of interest; litigation; share price fluctuations; limited market for securities; lack of dividends; environmental laws and regulations; economic environment; global economy risk; going-concern risk; and financial risk exposures.

The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company’s forward-looking statements. Neither the CSE nor its regulation services provider accepts responsibility for the adequacy or accuracy of this news release.

VANCOUVER, British Columbia, June 13, 2018 (GLOBE NEWSWIRE) — FinCanna Capital Corp. (“FinCanna”) (CSE:CALI) (OTCQB:FNNZF) a royalty company for the U.S. licensed medical cannabis industry announces that its portfolio investee company, ezGreen Compliance (“ezGreen”), which offers a state-of-the-art enterprise compliance and point-of-sale (POS) software solution for licensed medical cannabis dispensaries and cultivators, has launched its advanced “ezGreen Compliance 2.0” software solution.

Additionally, ezGreen has executed a strategic partnership agreement with a major technology solution provider in the cannabis industry to offer the ezGreen Compliance solution to its customer base of 1,000+ dispensaries across the United States.

Andriyko Herchak, President and CEO of FinCanna Capital, states, “Protecting patient data is one of the primary concerns of licensed medical dispensaries in the United States, and will no doubt be a focal point in state and federal regulations, as we’ve seen develop in the Pharma sector. The strategic partnership agreement gives ezGreen access to over one thousand dispensaries, with the potential to quickly begin generating sales, of which a percentage of the top line revenue will flow to FinCanna. This further validates our investment thesis in ezGreen and we look forward to being a part of their growth.”

The ezGreen Compliance 2.0 release is an add-on to the company’s existing POS application with new features related to dispensary and retail workflows, custom reporting for retail data sets, and key cannabis platform integrations including the heavy load of ever changing laws and compliance regulations.

As a further point of differentiation, ezGreen has achieved certification status with METRC, and as part of its ezGreen Compliance 2.0 release, is developing deep integration with their seed to sale tracking program.  The METRC tracking system was specifically designed for government agencies in charge of legalized marijuana enforcement.

The ezGreen Compliance 2.0 release also features:

• Enhanced Dispensary Station Workflow Capabilities;
• Product Automation for State Taxation and Reporting;
• Product Formulary Management Tools for Custom Retail Portal Needs.

Specifically developed to address the needs of the cannabis Industry, ezGreen Compliance is a HIPAA certified POS solution developed and supported by Automated HealthCare Solutions (AHCS).  AHCS is a leading point of care tracking and dispensing software solution developed over the past 16 years which currently supports 3,500+ active physician operated clinics and dispensaries, all while maintaining HIPAA compliance following essential Health and Human Services standards in the United States.

About ezGreen Compliance

ezGreen Compliance, located in Fort Lauderdale FL, provides through its ezGreen software technology, a proven state-of-the-art enterprise compliance and point-of-sale software solution for licensed medical cannabis dispensaries and cultivators. Navigating through state-by-state license, tax and compliance issues has been challenging for the legal cannabis industry. ezGreen Compliance helps its customers comply with both the Health Insurance Portability and Accountability Act (“HIPAA”) and State Laws by ensuring patients’ confidential data is being handled properly, helping to protect from possible security breaches and financial and criminal liability resulting from potential violations. For more information around a HIPAA compliance strategy for the Cannabis industry, please visit www.ezgreencompliance.com .

 About FinCanna Capital Corp.

FinCanna provides financing to top-tier companies in the licensed medical cannabis industry in exchange for a royalty on revenues.  FinCanna, led by a team of finance and industry experts, is building its diversified portfolio of royalty investments in scalable, best-in-class projects and companies in U.S. legal states, with a focus on California.  For additional information visit www.fincannacapital.com and FinCanna’s profile at www.sedar.com.

FinCanna Capital Corp.
Andriyko Herchak, CEO & Director

Investor Relations:
Arlen Hansen
Kin Communications
1-866-684-6730
CALI@kincommunications.com

Forward-Looking Information

Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions. All statements, other than statements of historical fact, included herein including, without limitation, statements about the market for, and effectiveness of, ezGreen software, the ability of ezGreen Compliance to expand operations and generate sales and revenues, the results of operations of Chameleon Collective, FinCanna’s ability to fund and source future projects, and FinCanna’s ability to earn and realize revenues from its investee companies.  By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the risks identified in the CSE listing statement available at www.SEDAR.com and other reports and filings with the applicable Canadian securities regulators. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made, and the respective companies undertake no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements.